Dr Lal PathLabs Expands to Tashkent With New Subsidiary

NEW DELHI / TASHKENT — Leading Indian diagnostic services provider Dr Lal PathLabs Limited announced on Wednesday, August 19, 2026, that it has expanded its international footprint by incorporating a new step-down subsidiary in Tashkent, Uzbekistan, named Dr Lal PathLabs Indomed LLC.

The strategic expansion is executed through the company’s wholly owned Dubai-based subsidiary, Dr Lal PathLabs FZCO. Under the agreement, the corporate group has committed to subscribing to 70% of the share capital of the newly formed Tashkent entity, positioning the diagnostics leader to tap into emerging healthcare markets across Central Asia.

Strategic International Growth and Diagnostic Footprint

The incorporation of Dr Lal PathLabs Indomed LLC marks a major step in the company's cross-border growth strategy. By establishing operational infrastructure in Tashkent, the diagnostics chain aims to introduce its advanced laboratory testing protocols, quality assurance standards, and comprehensive pathology services to patients and medical institutions in Uzbekistan.

According to official stock exchange filings, corporate disclosures, and regulatory notifications submitted under SEBI guidelines:

• Subsidiary Structure: The newly formed entity, Dr Lal PathLabs Indomed LLC, is established as a step-down subsidiary 70% owned by the group's Dubai subsidiary, Dr Lal PathLabs FZCO.

• Core Business Objectives: The subsidiary will focus on delivering advanced diagnostic services, clinical pathology testing, and health screening solutions in Tashkent.

• Corporate Governance: Regulatory filings confirm that the incorporation complies with all applicable disclosure standards, ensuring transparent financial structuring and arm's length execution.

• Financial Positioning: The international expansion coincides with robust consolidated financial performance, supported by strong cash reserves and steady revenue growth across domestic operations.

Official Sources Section

• National Stock Exchange of India (NSE) Corporate Filings: Official regulatory disclosures and material event notifications submitted by Dr Lal PathLabs Limited regarding the incorporation of Dr Lal PathLabs Indomed LLC.

• BSE India Corporate Disclosures: Exchange compliance archives and statutory reporting updates (BSE: LALPATHLAB).

• Dr Lal PathLabs Corporate Communications: Official press releases and international expansion updates.

Quote Section

According to statements released by corporate executives and regulatory disclosures regarding the international venture:

• "The incorporation of Dr Lal PathLabs Indomed LLC in Tashkent reflects our ongoing commitment to expanding our diagnostic expertise and bringing high-quality healthcare services to international markets."

Why It Matters

For international healthcare markets and institutional investors, expanding diagnostic networks into Central Asia diversifies revenue streams beyond the domestic market. Establishing a physical presence in Tashkent enables efficient healthcare delivery, strengthens regional medical partnerships, and extends world-class testing standards to new patient populations.

Key Facts at a Glance

• Parent Company: Dr Lal PathLabs Limited.

• New Entity: Dr Lal PathLabs Indomed LLC (Tashkent, Uzbekistan).

• Ownership Structure: 70% equity stake held via Dubai subsidiary Dr Lal PathLabs FZCO.

• Primary Sector: Diagnostic services, pathology, and clinical laboratory testing.

FAQ Section

What is the name of Dr Lal PathLabs' new subsidiary in Uzbekistan? The newly incorporated entity is named Dr Lal PathLabs Indomed LLC, located in Tashkent, Uzbekistan.

What percentage stake does Dr Lal PathLabs hold in the new entity? Through its Dubai-based subsidiary (Dr Lal PathLabs FZCO), the company has agreed to subscribe to 70% of the share capital of the Tashkent subsidiary.

What services will the Tashkent facility provide? The entity will focus on delivering advanced diagnostic services, clinical laboratory testing, and healthcare screening solutions.

Where can investors review official disclosures regarding this incorporation? Official regulatory filings, compliance notices, and material event disclosures are published directly on the BSE and NSE corporate portals.

Source: NSE India, BSE India, Dr Lal PathLabs, Sahi Markets